This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fritz E and Ludwig H (2000) Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3,948 patients. Ann Oncol 11: 1427–1436
Barlogie B et al. (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24: 929–936
Berenson JR et al. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99: 3163–3168
Richardson PG et al. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108: 3458–3464
Berenson JR et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488–493
Acknowledgements
The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Munshi, N., Mitsiades, C., Richardson, P. et al. Does maintenance therapy with thalidomide benefit patients with multiple myeloma?. Nat Rev Clin Oncol 4, 394–395 (2007). https://doi.org/10.1038/ncponc0847
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0847